Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth
Portfolio Pulse from
Myriad Genetics reported strong financial results for the fourth quarter and full-year 2024, with significant revenue growth driven by demand for Pharmacogenomics and Prenatal testing.
February 24, 2025 | 9:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Myriad Genetics reported a full-year 2024 revenue of $838 million, an 11% increase year-over-year, marking the second consecutive year of double-digit growth. The fourth quarter revenue was $211 million, up 7% year-over-year, driven by strong demand for Pharmacogenomics and Prenatal testing.
The reported double-digit revenue growth for the second consecutive year and strong demand in key testing areas are positive indicators for Myriad Genetics. The increase in gross margin and revenue per test trends further support a positive outlook.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100